BridgeBio Pharma (BBIO) Stock Price, News, Quotes-Moomoo

34.900
+0.650+1.90%

Close Feb 28 16:00 ET

34.900
0.0000.00%

Post 20:01 ET

6.64BMarket Cap-12.12P/E (TTM)

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Teddy123

Feb 28 06:51

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Tar

$Helix Acquisition Corp. II (HLXB.US)$ $BridgeBio Pharma (BBIO.US)$
$450M Deal Powers New Cancer-Fighting Biotech: What's Inside BridgeBio's Oncology SPAC Merger?

Teddy123

Feb 11 08:24

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

$BridgeBio Pharma (BBIO.US)$
BBIO Secures Major EU Win: Revolutionary Heart Drug Shows 42% Mortality Reduction

Jaguar8

Jan 13 20:08

🔵 Watchlist JANUARY 14,2025, Tuesday. NFA. DO NOT ENTER without buy momentum.

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...

李飞Allyssa : Doctor, can you please take a look at LAES?

Report
Reply

Cancel Reply
Jaguar8 OP 李飞Allyssa : Sorry I forgot haha WKEY and LAES are together

Report
Reply

Cancel Reply
李飞Allyssa : Hope it rebounds tomorrow, thank you very much for your efforts

Report
Reply

Cancel Reply
152390662 : May I ask where did you see the announcement for $LeddarTech (LDTC.US)$

Report
Reply

Cancel Reply
Jaguar8 OP 152390662 : QUEBEC CITY, Canada, Jan. 13, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.
Driving Innovation Through Strategic Partnerships
With the successful CES 2025 demonstration of LeddarVision Surround (LVS-2+) software utilizing Texas Instruments (“TI”) TDA4VH-Q1 processor, LeddarTech has now received the second advanced royalty payment of US$ 3 million as part of its licensing agreement. This partnership, announced in early December 2024, aims to capitalize on the integration of LeddarTech’s groundbreaking LeddarVision software into TI’s scalable portfolio of processors to create a comprehensive platform for advanced driver assistance systems (ADAS) and autonomous driving (AD) markets. The collaboration signifies a pivotal step forward in delivering cutting-edge solutions to automotive OEMs and Tier 1 suppliers, underscoring LeddarTech’s commitment to innovation and leadership.
Customer and Partner Enthusiasm at CES 2025
At CES 2025 in Las Vegas, LeddarTech showcased its LeddarVision Surround-View (LVS-2+), a state-of-the-art software stack tailored for L2/L2+ highway and city ADAS applications. This breakthrough technology addresses critical challenges the automotive industry faces, setting new benchmarks in safety and performance and enabling automotive manufacturers to cost-effectively meet 5-star NCAP 2025/GSR 2022 requirements.

Report
Reply

Cancel Reply

View more comments...

Jaguar8

Jan 13 16:18

NEWS

$BridgeBio Pharma (BBIO.US)$
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
BridgeBio Pharma (NASDAQ: BBIO)reported significant commercial progress for its recently FDA-approved drug Attruby, with 430 prescriptions written by 248 unique physicians for ATTR-CM treatment. The company announced the completion of enrollment in three major Phase 3 clinical trials: FORTIFY (112 patients for LGMD2I/R9), CALIBRATE (70 patients for ADH1), and PROPEL 3 (114 participants f...

105069706

Jan 13 16:17

$BridgeBio Pharma (BBIO.US)$ https://www.moomoo.com/news/flash/19740696?futusource=news_stock_stockpagenews&ns_stock_id=77584289451605&src=2&stock_news_tab=news&main_broker=WzEwMTdd&my_cid=105069706&client_hour_clock=24&channel=4&skintype=3&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Aflash%3A19740696%22%2C%22invite%22%3A105069706%7D&data_ticket=53ba4dd539203616519b031b3b8738f8

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More

BBIO BridgeBio Pharma

Trade Overview

Capital Trend

News

Comments

Trending Stocks